Digital Endpoint for Assessing Nocturnal Scratching in Atopic Dermatitis
Food and Drug Administration · United States
Time Left to Bid
Awarded
Basic information
- Reference number
- 75F40124C00013
- Issuing organization
- Food and Drug Administration · Find award history →
- Government level
- Federal
- Solicitation type
- Other
- Title
- Digital Endpoint for Assessing Nocturnal Scratching in Atopic Dermatitis
- Source
- USASpending (Federal)
- Source ID
- usa-75F40124C00013
Details
- Location
- United States
Summary
A research project aimed at creating a quantitative, user-friendly digital endpoint to assess nocturnal scratching in pediatric atopic dermatitis patients. The tool will provide an objective method to evaluate treatment efficacy and patient symptoms.
Description
THE GOAL OF THIS PROJECT IS TO DEVELOP AN OBJECTIVE, QUANTITATIVE, AND USER-FRIENDLY DIGITAL ENDPOINT TO ASSESS NOCTURNAL SCRATCHING IN CHILDREN WITH ATOPIC DERMATITIS. THIS ENDPOINT WILL FULFILL A CRUCIAL UNMET NEED BY FOR ASSESSING THE EFFICACY Awarded to: EMERALD INNOVATIONS, INC. Agency: Department of Health and Human Services Sub-agency: Food and Drug Administration Award type: DEFINITIVE CONTRACT
Dates
- Publication
- 2023/12/06 12:00:00 AM UTC
- Closing date
- 2028/05/29 12:00:00 AM UTC
Estimated value
$2.0M USD
Classification
Normalized category